Apidel’s technology is the subject of a peer reviewed publication


A new paper with the title "Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster…

Read More

Apidel amongst the TOP100 startups in Switzerland!


“Each year, "startup.ch" launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung. From over 100,000 young companies, the…

Read More

Apidel’s technology is the subject of a peer reviewed publication


A recent article published in the journal "Molecular Pharmaceutics" has described a study reporting enhanced delivery of tacrolimus into…

Read More

Apidel appoints Alliance Manager


On March 1st, 2014, Apidel has announced the appointment of Victoria Sarraf as its Alliance Manager. Victoria will be based at Apidel's…

Read More

Apidel receives grant of US patent


On January 17th, 2014, Apidel received notice from the United States Patent Office that its patent application US 13/778,038 would be…

Read More

Apidel increases facility space, adds new employee


On October 21st, 2013, Apidel has announced an increase to its laboratory and office spaces, located in the Geneva area. The company has…

Read More

US Patent granted


US patent 8,466,133 "Polylactide Compositions and Uses Thereof" granted by the United States' Patent Office ! This patent protects the…

Read More

4th feasibility agreement


Apidel signs with one of the largest companies in the world for a new ophthalmic drug product using our ApidSOL™ technology.

Read More

3rd feasibility agreement


Apidel signs a third feasibility study with a major player in dermatology for two new drug products using our ApidSOL™ technology.

Read More

2nd feasibility agreement


Apidel signs a feasibility agreement for a sustained-release formulation using ApidCOR™ with one of the largest pharmaceutical companies…

Read More